{"component": "definition", "props": {"groups": [{"snippet_links": [], "snippet": "has the meaning set forth in Section 10.7(c)(ix).", "samples": [{"hash": "jDTZ2wOfu1C", "uri": "/contracts/jDTZ2wOfu1C#reversion-ip", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.5242977142, "published": true}, {"hash": "elvknFyTYBd", "uri": "/contracts/elvknFyTYBd#reversion-ip", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.3709793091, "published": true}, {"hash": "gizMheTuIY8", "uri": "/contracts/gizMheTuIY8#reversion-ip", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.2258720398, "published": true}], "size": 6, "hash": "ce6caabbde94bbd99bd1163a4d2e24b0", "id": 1}, {"snippet_links": [{"key": "by-regeneron", "type": "clause", "offset": [41, 53]}, {"key": "date-of-notice-of-termination", "type": "definition", "offset": [86, 115]}, {"key": "for-purposes-hereof", "type": "definition", "offset": [127, 146]}, {"key": "reversion-products", "type": "definition", "offset": [149, 167]}], "snippet": "means any Patents or Know-How Controlled by Regeneron or any its Affiliates as of the date of notice of termination that [***] For purposes hereof, \u201cReversion Products\u201d shall mean [***].", "samples": [{"hash": "78LVdQVCpeu", "uri": "/contracts/78LVdQVCpeu#reversion-ip", "label": "License and Collaboration Agreement (Intellia Therapeutics, Inc.)", "score": 33.3394927979, "published": true}, {"hash": "7jVz9mYByjQ", "uri": "/contracts/7jVz9mYByjQ#reversion-ip", "label": "License and Collaboration Agreement (Intellia Therapeutics, Inc.)", "score": 27.3408622742, "published": true}, {"hash": "1bTMFZYevBf", "uri": "/contracts/1bTMFZYevBf#reversion-ip", "label": "License and Collaboration Agreement (Intellia Therapeutics, Inc.)", "score": 27.3189601898, "published": true}], "size": 4, "hash": "e849c4cb7d421811ac7f2ed170649c1e", "id": 2}, {"snippet_links": [{"key": "joint-patents", "type": "clause", "offset": [48, 61]}, {"key": "at-any-time", "type": "clause", "offset": [129, 140]}, {"key": "during-the-term", "type": "clause", "offset": [141, 156]}, {"key": "of-activities", "type": "clause", "offset": [169, 182]}, {"key": "in-connection-with", "type": "clause", "offset": [183, 201]}, {"key": "in-existence", "type": "definition", "offset": [226, 238]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [257, 286]}, {"key": "by-precision", "type": "clause", "offset": [309, 321]}, {"key": "section-1421", "type": "clause", "offset": [334, 348]}, {"key": "section-1422", "type": "clause", "offset": [350, 364]}, {"key": "section-1423", "type": "clause", "offset": [368, 382]}, {"key": "in-accordance-with", "type": "clause", "offset": [395, 413]}, {"key": "for-any-reason", "type": "clause", "offset": [430, 444]}, {"key": "the-events", "type": "clause", "offset": [460, 470]}, {"key": "section-1425", "type": "clause", "offset": [530, 544]}, {"key": "reasonably-necessary", "type": "clause", "offset": [557, 577]}, {"key": "the-development", "type": "clause", "offset": [607, 622]}, {"key": "reversion-products", "type": "definition", "offset": [665, 683]}, {"key": "in-the-territory", "type": "clause", "offset": [684, 700]}], "snippet": "means any Baxalta Patents, Baxalta Know-How and Joint Patents that (a) come to be Controlled by Baxalta or any of its Affiliates at any time during the Term as a result of activities in connection with this Agreement, (b) are in existence as of the date of termination of this Agreement (in whole or in part) by Precision pursuant to Section 14.2.1, Section 14.2.2 or Section 14.2.3, by Baxalta in accordance with Section 14.2.1 (for any reason other than for the events described in Section 14.3.2(a)), or by Baxalta pursuant to Section 14.2.5 and (c) are reasonably necessary or useful in connection with the Development, manufacture, use or Commercialization of Reversion Products in the Territory.", "samples": [{"hash": "k0sdhUE1UCf", "uri": "/contracts/k0sdhUE1UCf#reversion-ip", "label": "Development and Commercial License Agreement (Precision Biosciences Inc)", "score": 30.1937026978, "published": true}, {"hash": "4naiH06NA7C", "uri": "/contracts/4naiH06NA7C#reversion-ip", "label": "Development and Commercial License Agreement (Precision Biosciences Inc)", "score": 29.988363266, "published": true}, {"hash": "lOx0UotXCM4", "uri": "https://investor.precisionbiosciences.com/static-files/69ceadc2-96b0-4994-8bc1-9d23bd31f745", "label": "Amendment", "score": 14.1704311371, "published": false}], "size": 3, "hash": "b70402f492750d3ae077ea4411dd9999", "id": 3}, {"snippet_links": [{"key": "patent-rights", "type": "definition", "offset": [10, 23]}, {"key": "licensed-compounds", "type": "definition", "offset": [117, 135]}, {"key": "licensed-products", "type": "definition", "offset": [139, 156]}, {"key": "the-last-sentence", "type": "clause", "offset": [169, 186]}, {"key": "method-of-manufacture", "type": "clause", "offset": [226, 247]}, {"key": "date-of-notice-of-termination", "type": "definition", "offset": [306, 335]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [392, 414]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [506, 546]}, {"key": "in-no-event-will", "type": "clause", "offset": [555, 571]}, {"key": "owned-or-controlled", "type": "definition", "offset": [584, 603]}, {"key": "for-clarity", "type": "clause", "offset": [659, 670]}, {"key": "combination-products", "type": "definition", "offset": [733, 753]}, {"key": "the-license", "type": "definition", "offset": [782, 793]}], "snippet": "means any patent rights or Know-How Controlled by FBIO or any its Affiliates or Sublicensees that claim or cover any Licensed Compounds or Licensed Products (subject to the last sentence of this Section 10.7(c)(ix)), or their method of manufacture or use, as such patent rights or Know-How exist as of the date of notice of termination (including any other patent right that claims priority, directly or indirectly, to any such patent right, no matter when any such other patent right is filed or issued). Notwithstanding anything to the contrary herein, in no event will any product owned or Controlled by FBIO or its Affiliates or Sublicensees (other than, for clarity, any Licensed Compounds or Licensed Products (i.e., excluding Combination Products)) be included or subject to the license set forth in this Section 10.7(c)(ix).", "samples": [{"hash": "jDTZ2wOfu1C", "uri": "/contracts/jDTZ2wOfu1C#reversion-ip", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.5242977142, "published": true}, {"hash": "elvknFyTYBd", "uri": "/contracts/elvknFyTYBd#reversion-ip", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.3709793091, "published": true}, {"hash": "gizMheTuIY8", "uri": "/contracts/gizMheTuIY8#reversion-ip", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.2258720398, "published": true}], "size": 3, "hash": "1d055aa4ff85267912fce3ed12d2f087", "id": 4}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "reversion-compound", "type": "definition", "offset": [27, 45]}, {"key": "reversion-product", "type": "definition", "offset": [49, 66]}, {"key": "method-of-manufacture", "type": "clause", "offset": [171, 192]}, {"key": "date-of-notice-of-termination", "type": "definition", "offset": [210, 239]}, {"key": "the-applicable", "type": "clause", "offset": [382, 396]}, {"key": "prior-to", "type": "clause", "offset": [417, 425]}, {"key": "licensed-ip", "type": "clause", "offset": [520, 531]}], "snippet": "means, with respect to any Reversion Compound or Reversion Product, any Patents or Information that (a) claim or cover such Reversion Compound or Reversion Product or its method of manufacture or use as of the date of notice of termination, (b) are Controlled by Anchiano or any of its Affiliates, and (c) were used or are being used by Anchiano or any of its Affiliates to Exploit the applicable Compound or Product prior to or as of the date of notice of termination; provided, however, Reversion IP shall not include Licensed IP.", "samples": [{"hash": "frcVjxXfl3l", "uri": "/contracts/frcVjxXfl3l#reversion-ip", "label": "Collaboration and License Agreement (Anchiano Therapeutics Ltd.)", "score": 32.0335388184, "published": true}, {"hash": "1qzwMa4VN6H", "uri": "/contracts/1qzwMa4VN6H#reversion-ip", "label": "Collaboration and License Agreement (Anchiano Therapeutics Ltd.)", "score": 30.7248458862, "published": true}], "size": 2, "hash": "3385ed51fc60c1a0e2b7697029f92580", "id": 5}, {"snippet_links": [{"key": "by-gilead", "type": "clause", "offset": [51, 60]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [104, 133]}, {"key": "for-clarity", "type": "clause", "offset": [171, 182]}, {"key": "prior-to", "type": "clause", "offset": [285, 293]}, {"key": "necessary-for", "type": "definition", "offset": [314, 327]}, {"key": "the-development", "type": "clause", "offset": [350, 365]}, {"key": "licensed-products", "type": "definition", "offset": [403, 420]}, {"key": "regulatory-authority", "type": "clause", "offset": [509, 529]}, {"key": "required-modifications", "type": "clause", "offset": [530, 552]}, {"key": "in-the-case", "type": "clause", "offset": [643, 654]}, {"key": "active-component", "type": "definition", "offset": [701, 717]}, {"key": "in-combination", "type": "definition", "offset": [817, 831]}, {"key": "other-active", "type": "definition", "offset": [846, 858]}], "snippet": "means any Patents and Know-How that are Controlled by Gilead or any of its Affiliates as of the date of termination of this Agreement (in whole or in part, and including, for clarity, Patents filed or issued at any later date covering or claiming applicable inventions conceived on or prior to such date) that are necessary for Precision to continue the Development, Manufacture, use or Exploitation of Licensed Products in the form existing as of the date of termination of this Agreement (and including any Regulatory Authority-required modifications made thereto after such date), excluding any Patent or Know-How that covers or claims, or in the case of Know-How, relates specifically to, (i) any Active Component of any Licensed Product that is not a Gilead ARC Nuclease or (ii) any use of a Gilead ARC Nuclease in combination with any such other Active Component of such Licensed Product.", "samples": [{"hash": "bprHOJlo4Mt", "uri": "/contracts/bprHOJlo4Mt#reversion-ip", "label": "Collaboration and License Agreement (Precision Biosciences Inc)", "score": 30.1937026978, "published": true}, {"hash": "iZEuddiTcoc", "uri": "/contracts/iZEuddiTcoc#reversion-ip", "label": "Collaboration and License Agreement (Precision Biosciences Inc)", "score": 29.7967147827, "published": true}], "size": 2, "hash": "351e9b4b34743ab8c53e6114d4e65a65", "id": 6}, {"snippet_links": [{"key": "in-clause", "type": "clause", "offset": [22, 31]}], "snippet": "has the meaning given in Clause 33.2(d).", "samples": [{"hash": "8sjCjK9Pm0m", "uri": "/contracts/8sjCjK9Pm0m#reversion-ip", "label": "Collaboration and License Agreement (Exscientia PLC)", "score": 34.22108078, "published": true}, {"hash": "6az2w70bfBX", "uri": "/contracts/6az2w70bfBX#reversion-ip", "label": "Collaboration and License Agreement (Exscientia PLC)", "score": 33.2217674255, "published": true}], "size": 2, "hash": "1a0cc4c6cde5f095efe16042f724459f", "id": 7}, {"snippet_links": [{"key": "patent-rights", "type": "definition", "offset": [10, 23]}, {"key": "by-licensee", "type": "clause", "offset": [47, 58]}, {"key": "licensed-compounds", "type": "definition", "offset": [112, 130]}, {"key": "licensed-products", "type": "definition", "offset": [134, 151]}, {"key": "the-last-sentence", "type": "clause", "offset": [164, 181]}, {"key": "method-of-manufacture", "type": "clause", "offset": [217, 238]}, {"key": "date-of-notice-of-termination", "type": "definition", "offset": [297, 326]}, {"key": "directly-or-indirectly", "type": "clause", "offset": [383, 405]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [497, 537]}, {"key": "in-no-event-will", "type": "clause", "offset": [546, 562]}, {"key": "owned-or-controlled", "type": "definition", "offset": [587, 606]}, {"key": "for-clarity", "type": "clause", "offset": [666, 677]}, {"key": "to-the-extent", "type": "clause", "offset": [731, 744]}, {"key": "active-ingredient", "type": "clause", "offset": [822, 839]}, {"key": "combination-products", "type": "definition", "offset": [857, 877]}, {"key": "the-license", "type": "definition", "offset": [906, 917]}], "snippet": "means any patent rights or Know-How Controlled by Licensee or any its Affiliates or Sublicensees that [***] any Licensed Compounds or Licensed Products (subject to the last sentence of this Section 12.6(f)), or their method of manufacture or use, as such patent rights or Know-How exist as of the date of notice of termination (including any other patent right that claims priority, directly or indirectly, to any such patent right, no matter when any such other patent right is filed or issued). Notwithstanding anything to the contrary herein, in no event will any compound or product owned or controlled by Licensee or its Affiliates or Sublicensees (other than, for clarity, any Licensed Compounds or Licensed Products (solely to the extent that any such Licensed Product contains only a Licensed Compound as the sole active ingredient (i.e., excluding Combination Products)) be included or subject to the license set forth in this Section 12.6(f).", "samples": [{"hash": "iC8LAwvOPP7", "uri": "/contracts/iC8LAwvOPP7#reversion-ip", "label": "License Agreement (Celgene Corp /De/)", "score": 25.5722103119, "published": true}], "size": 1, "hash": "fb13d81dd2826bec3c0b4b694397473f", "id": 8}, {"snippet_links": [{"key": "effective-date-of-termination", "type": "definition", "offset": [65, 94]}, {"key": "reversion-product", "type": "definition", "offset": [133, 150]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [228, 252]}], "snippet": "means Patents or Know-How Controlled by Vir as of the applicable effective date of termination that are (a) necessary to Exploit any Reversion Product as it exists as of such effective date of termination, or (b) planned by Vir as of the effective date of termination to be used to further optimize or remedy known safety or efficacy issues with such Reversion Product, as evidenced by reasonable contemporaneous documentation.", "samples": [{"hash": "4u1SXt2g5yq", "uri": "/contracts/4u1SXt2g5yq#reversion-ip", "label": "License Agreement (Vir Biotechnology, Inc.)", "score": 35.8418884277, "published": true}], "size": 1, "hash": "b01cae20d2f3c0be8f38b8804549b6d9", "id": 9}, {"snippet_links": [{"key": "patent-rights", "type": "definition", "offset": [24, 37]}, {"key": "termination-of-this-agreement", "type": "clause", "offset": [87, 116]}], "snippet": "means any Coformulation Patent Rights Controlled by Acumen as of the effective date of termination of this Agreement. 1.", "samples": [{"hash": "1kIAXTb7ulq", "uri": "/contracts/1kIAXTb7ulq#reversion-ip", "label": "Collaboration, Option, and License Agreement (Acumen Pharmaceuticals, Inc.)", "score": 33.6112251882, "published": true}], "size": 1, "hash": "fbae1605816e6630755c5ae7368fb916", "id": 10}], "next_curs": "ClkSU2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjULEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIVcmV2ZXJzaW9uLWlwIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"snippet": "has the meaning set forth in Section 10.7(c)(ix).", "title": "Reversion IP", "size": 28, "id": "reversion-ip", "examples": ["At Cephalon\u2019s written request, the Parties will enter into commercially reasonable prosecution, maintenance, enforcement and defense terms for the exclusively licensed <strong>Reversion IP</strong>, and Cephalon will bear the costs of such prosecution, maintenance, enforcement and defense activities to the extent controlled by Cephalon.", "It is understood and agreed that with respect to any <strong>Reversion IP</strong> that is in-licensed by FBIO or any of its Affiliates or Sublicensees, Cephalon will be responsible for any payments due to a Third Party with respect thereto and Cephalon\u2019s rights will be subject to the terms of the applicable Third Party agreement.", "Effective as of the effective date of termination, Company hereby grants to Maze a non-exclusive, transferrable (pursuant to Section 14.4 (Assignment)) and sublicensable (through multiple tiers) license under the Company <strong>Reversion IP</strong> solely as necessary to Research, Develop, Manufacture, Commercialize or otherwise Exploit the Licensed Product(s) in the Field in the Territory.", "In the event of termination of this Agreement [***], GNE shall grant to Immunocore a right to negotiate the commercially reasonable terms under which GNE may grant Immunocore the right for a transfer of all material activities including any ongoing Clinical Trials directly relating to the Terminated Product(s) and a license under the GNE <strong>Reversion IP</strong> for such Terminated Product(s) (collectively, the \u201cR\u2587\u2587\u201d).", "At SGI\u2019s written request, the Parties will enter into commercially reasonable agreement addressing patent prosecution, enforcement and defense for the Unum <strong>Reversion IP</strong> consistent with the principles set forth in Article 11, and SGI will bear the costs of such prosecution, enforcement and defense activities to the extent controlled by SGI.", "It is understood and agreed that the grant of the license under the GNE <strong>Reversion IP</strong> may be: [***].", "Such license will be exclusive (even as to Baxalta and its Affiliates) or non-exclusive, on a Patent-by-Patent basis, based on Precision\u2019s election made in a written notice to Baxalta with respect to each of the Patents included in the <strong>Reversion IP</strong> (\u201cReversion Patents\u201d).", "At Unum\u2019s written request, the Parties will enter into commercially reasonable agreement addressing patent prosecution, enforcement and defense for the SGI <strong>Reversion IP</strong> consistent with the principles set forth in Article 11, and Unum will bear the costs of such prosecution, enforcement and defense activities to the extent controlled by Unum.", "Gilead hereby represents and warrants to SR that neither Gilead nor any of its Affiliates Control as of December 19, 2021 any Know-How or Patents that would be Gilead <strong>Reversion IP</strong>.", "The foregoing license under the AbbVie <strong>Reversion IP</strong> shall be payable on a country-by-country basis and [***] (applied mutatis mutandis to Harpoon) by Harpoon, its Affiliates or sublicensees of Harpoon Reversion Products, beginning [***]."], "related": [["collaboration-ip", "Collaboration IP", "Collaboration IP"], ["foreground-ipr", "Foreground IPR", "Foreground IPR"], ["foreground-ip", "Foreground IP", "Foreground IP"], ["developed-technology", "Developed Technology", "Developed Technology"], ["transferred-technology", "Transferred Technology", "Transferred Technology"]], "related_snippets": [], "updated": "2025-08-15T04:21:20+00:00"}, "json": true, "cursor": ""}}